BACKGROUND The aim of our study was to identify the optimal predictor of prostate cancer among several prostate-specific antigen (PSA) derivatives in repeat prostate biopsy. METHODS We retrospectively assessed the repeat prostate biopsy specimens, obtained between 1999 and 2008, of 212 patients with a total PSA (tPSA) of 4-10 ng/ml and normal digital rectal examination. Using a receiver opera...

The development of increasingly specific diagnostic assays has allowed the detection of various forms of prostate-specific antigen (PSA). It has been found that the proportion of free to total PSA (percent free PSA) is significantly lower in men with prostate cancer than in those with other benign diseases. In order to distinguish early, curable prostate cancer from benign prostatic hyperplasia...

INTRODUCTION PSA parameters have been used in an attempt to improve the diagnostic yield of prostate screening tests; the detection of primary malignant circulating prostate cells (CPCs) may improve the diagnostic yield of screening and therefore avoid unnecessary biopsies. PATIENTS AND METHODS Prospective study of all men undergoing initial prostate biopsy due to an elevated total serum PSA....

Background: Because total prostate-specific antigen (PSA) and, more recently, the percent free PSA are used to screen men for prostate cancer, population-based, ageand racespecific distributions are needed of both PSA tests among American men to estimate the effect of lowering the PSA threshold or widespread introduction of the free PSA test as an additional screening test. Methods: We did PSA ...

BACKGROUND The combined use of free and total prostate-specific antigen (PSA) in early detection of prostate cancer has been controversial. This article systematically evaluates the discriminating capacity of a large number of combination tests. METHODS Free and total PSA were analyzed in stored serum samples taken prior to diagnosis in 429 cases and 1,640 controls from the Physicians' Health...

We compared two recently introduced commercial assays (CanAg and Immulite) for measuring free prostate-specific antigen (f-PSA), total PSA (t-PSA), and the ratio of t-PSA/f-PSA (f-PSA%) in control materials and sera of 54 healthy men, 50 patients with benign prostatic hyperplasia (BPH), and 45 patients with prostate cancer (PCa). The lower detection limits for f-PSA were 0.038 microgram/L and 0...

OBJECTIVE To assess the cost-effectiveness of two diagnostic strategies for prostate cancer in men with prostate-specific antigen (PSA) levels of 4-10 ng/ml and normal digital rectal examination (DRE). DESIGN Cost-effectiveness analysis was performed using a decision tree model. Data collection and a systematic review of patients at the Urology Department (Carlos Haya Hospital) were made. 101...

background: the normal prostate-specific antigen (psa) level in patients with urethral catheterization is a controversy. we designed this study to investigate the effect of nontraumatic urethral catheterization without urinary retention on serum psa. materials and methods: seventy patients scheduled for urethral catheterization before elective surgeries were randomly selected and included in th...

PURPOSE The most appropriate definition of biochemical progression after radical prostatectomy and radiation therapy is uncertain. We analyzed the effect of using various prostate specific antigen (PSA) end point definitions for defining biochemical progression after radical prostatectomy and attempted to determine the best PSA cut point to use. Aspects of the American Society for Therapeutic R...